Anocca Appoints New Senior Management Roles and Expands Scientific Teams

Brian has a wealth of experience in shaping and enabling collaborations that create shared value, developed through a career in strategy consulting and corporate positions with GlaxoSmithKline. Brian has a wealth of experience in shaping and enabling collaborations that create shared value, developed through a career in strategy consulting and corporate positions with GlaxoSmithKline. "HLA restriction of targets and characterisation of TCRs in this complex space are critical challenges...

Brian has a wealth of experience in shaping and enabling collaborations that create shared value, developed through a career in strategy consulting and corporate positions with GlaxoSmithKline.

"HLA restriction of targets and characterisation of TCRs in this complex space are critical challenges that limit T cell therapy today. Anocca uses a systematic and industrial approach to decode T cell biology and I'm looking forward to finding partners with a shared desire to bring our transformative libraries of TCR assets to patients in need," said Brian McGee, incoming CBO, Anocca.

"Anocca continues to attract exceptional talent to our business. The knowledge, skills and experience of Mark, Brian and the new data science and scientific team members will be crucial as we expand our asset libraries and prepare to enter the clinic. Developing partnerships with peer biotech companies to access complementary technologies, and with pharmaceutical companies, will be critical to accelerating the clinical development and commercialisation of Anocca's highly precise T-cell therapeutics," said Reagan Jarvis, CEO and co-founder, Anocca.

Media contacts:

Anocca
Chief Development Officer
Mark Farmery
[email protected] 

Scius Communications (for international media)
Katja Stout
[email protected]

Daniel Gooch
[email protected]

About Anocca

Anocca combines functional biology, industrial biotechnology and advanced data sciences to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. The company's innovative approach to deciphering T cell immunity can reach an unprecedented number of druggable targets in oncology and other therapeutic areas, such as infectious diseases and autoimmune disorders. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company's platform has generated a broad pipeline of high value assets focusing on distinct disease franchises.

Anocca was founded in 2014 and is led by an experienced management team that has raised over USD 100 million in funding from leading Nordic investors including, Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco and Michano. Anocca's team of over 70 employees operates from its site in Södertälje, Sweden. To learn more about Anocca, please visit www.anocca.com and follow our LinkedIn.